{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:57Z","timestamp":1786993557730,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["S72"],"award-info":[{"award-number":["S72"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["AT 097882\/Z\/11\/Z"],"award-info":[{"award-number":["AT 097882\/Z\/11\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010876","name":"Vasculitis UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["SPM G0901997"],"award-info":[{"award-number":["SPM G0901997"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MP MR\/M018733\/1"],"award-info":[{"award-number":["MP MR\/M018733\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012912","name":"Imperial College Healthcare Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.kint.2019.12.014","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T11:17:58Z","timestamp":1579173478000},"page":"1196-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Spleen tyrosine kinase inhibition is an effective\u00a0treatment for established vasculitis in\u00a0a\u00a0pre-clinical model"],"prefix":"10.1016","volume":"97","author":[{"given":"Stephen P.","family":"McAdoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prendecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Tanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejal","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjeet","family":"Bhangal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McDaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban S.","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Pusey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.12.014_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.kint.2019.12.014_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.kint.2019.12.014_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4155\/ppa.14.34","article-title":"New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013","volume":"3","author":"Thorarensen","year":"2014","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.kint.2019.12.014_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1681\/ASN.2009030263","article-title":"A\u00a0spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis","volume":"21","author":"Smith","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.12.014_bib5","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1681\/ASN.2013090978","article-title":"Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN","volume":"25","author":"McAdoo","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.12.014_bib6","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.4049\/jimmunol.1102603","article-title":"Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients","volume":"189","author":"Kim","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2019.12.014_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2019.12.014_bib8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/01.ASN.0000113241.98702.77","article-title":"Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18","volume":"15","author":"Hewins","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.12.014_bib9","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1182\/blood-2005-03-0921","article-title":"Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in\u00a0vivo","volume":"106","author":"Little","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.kint.2019.12.014_bib10","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2353\/ajpath.2009.080458","article-title":"Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis","volume":"174","author":"Little","year":"2009","journal-title":"AmJ Pathol"},{"key":"10.1016\/j.kint.2019.12.014_bib11","doi-asserted-by":"crossref","first-page":"L497","DOI":"10.1152\/ajplung.00246.2004","article-title":"Syk tyrosine kinase participates in beta1-integrin signaling and inflammatory responses in airway epithelial cells","volume":"288","author":"Ulanova","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.kint.2019.12.014_bib12","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/MCB.26.9.3478-3491.2006","article-title":"Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase","volume":"26","author":"Zhou","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2019.12.014_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/ki.2015.29","article-title":"Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression","volume":"88","author":"McAdoo","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.12.014_bib14","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1089\/ars.2009.2538","article-title":"Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease","volume":"11","author":"van der Veen","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.kint.2019.12.014_bib15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ndt\/gfv384","article-title":"Impact of anti-glomerular basement membrane antibodies and glomerular neutrophil activation on glomerulonephritis in experimental myeloperoxidase-antineutrophil cytoplasmic antibody vasculitis","volume":"31","author":"Kanzaki","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.12.014_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/path.4598","article-title":"Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase","volume":"238","author":"Ryan","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.kint.2019.12.014_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature04489","article-title":"Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans","volume":"439","author":"Aitman","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.kint.2019.12.014_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/ng.137","article-title":"Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility","volume":"40","author":"Behmoaras","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2019.12.014_bib19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1681\/ASN.2009090968","article-title":"Genetic loci modulate macrophage activity and glomerular damage in experimental glomerulonephritis","volume":"21","author":"Behmoaras","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.12.014_bib20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1189\/jlb.71.6.996","article-title":"Wegener's granulomatosis: antiproteinase 3 antibodies induce monocyte cytokine and prostanoid release-role of autocrine cell activation","volume":"71","author":"Hattar","year":"2002","journal-title":"J\u00a0Leukocyte Biol"},{"key":"10.1016\/j.kint.2019.12.014_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J","article-title":"Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in\u00a0vitro","volume":"44","author":"Weidner","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2019.12.014_bib22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1172\/JCI119662","article-title":"Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors","volume":"100","author":"Ralston","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2019.12.014_bib23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.185.7.1371","article-title":"RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis","volume":"185","author":"Lloyd","year":"1997","journal-title":"J\u00a0ExpMed"},{"key":"10.1016\/j.kint.2019.12.014_bib24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1096\/fasebj.10.12.8903512","article-title":"Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF\/MCP-1)","volume":"10","author":"Wada","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2019.12.014_bib25","first-page":"536","article-title":"Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis","volume":"71","author":"Rovin","year":"1994","journal-title":"Lab invest"},{"key":"10.1016\/j.kint.2019.12.014_bib26","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","article-title":"Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis","volume":"19","author":"Tam","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.12.014_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfy300","article-title":"Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"35","author":"Moran","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.12.014_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.immuni.2012.11.015","article-title":"The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway","volume":"38","author":"Schweighoffer","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.kint.2019.12.014_bib29","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.1500461","article-title":"Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival","volume":"194","author":"Ackermann","year":"2015","journal-title":"J\u00a0immunol"},{"key":"10.1016\/j.kint.2019.12.014_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneph.2016.18","article-title":"Biologics for the treatment of autoimmune renal diseases","volume":"12","author":"Holdsworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2019.12.014_bib31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.kint.2019.12.014_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.175","article-title":"In\u00a0vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib","volume":"3","author":"Rolf","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.kint.2019.12.014_bib33","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.kint.2019.12.014_bib34","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/labinvest.2011.137","article-title":"Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis","volume":"91","author":"Ryan","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2019.12.014_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/2058738418783404","article-title":"An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis","volume":"32","author":"Han","year":"2018","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.kint.2019.12.014_bib36","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2019.12.014_bib37","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.12.014_bib38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2019.12.014_bib39","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2019.12.014_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1681\/ASN.2006010050","article-title":"Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6","volume":"18","author":"Sheryanna","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820300259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820300259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:54:25Z","timestamp":1777474465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820300259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0085253820300259"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.12.014","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spleen tyrosine kinase inhibition is an effective\u00a0treatment for established vasculitis in\u00a0a\u00a0pre-clinical model","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}